Value of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in the diagnosis of lung and mediastinal lesions

OBJECTIVE: To evaluate the value of EBUS-TBNA in the diagnosis of lung and mediastinal lesions.

METHODS: Prospective cohort study that included 52 patients during a 2-year period (2016 to 2018) who underwent EBUS-TBNA.

RESULTS: Among the 52 individuals submitted to the procedure, 22 (42.31%) patients were diagnosed with locally advanced lung cancer (N2 or N3 lymph node involvement). EBUS-TBNA confirmed the diagnosis of metastases from other extrathoracic tumors in the mediastinum or lung in 5 patients (9.61%), confirmed small cell lung cancer in 3 patients (5.76%), mediastinal sarcoidosis in 1 patient (1.92%), and reactive mediastinal lymph node in 8 patients (15.38%); insufficient results were found for 3 patients (5.76%). Based on these results, EBUS-TBNA avoided further subsequent surgical procedures in 39 of 52 patients (75%). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 86%, 100%, 100%, 77%, and 90%, respectively. No major complications were observed.

CONCLUSIONS: EBUS-TBNA is a safe, effective, and valuable method. This technique can significantly reduce the rate of subsequent surgical procedures required for the diagnosis of lung and mediastinal lesions.

KEYWORDS: Lung neoplasms. Lymph nodes. Biopsy, needle/methods. Mediastinal diseases/diagnosis. Endoscopic ultrasound-guided fine-needle aspiration. Image-guided biopsy.
INTRODUCTION

Various thoracic diseases, benign or malignant, include lung and mediastinal lesions, with varied etiologies and different evolutions. Given this wide variety of diseases, it is critical to make a definitive histopathological diagnosis so that patients can be offered the most appropriate and effective treatment. Different diagnostic modalities are available, including bronchoscopy with transbronchial biopsy, computed tomography-guided fine-needle aspiration, mediastinoscopy, thoracoscopy, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), and, more recently, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Each of these procedures has specific indications, risks and benefits, and different statistical results, availability, and costs.

EBUS-TBNA is considered a minimally invasive procedure, performed under sedation on an outpatient basis. The method allows real-time evaluation of lung and mediastinal lesions, located adjacent to the main airways. In addition to lung cancers, EBUS-TBNA plays an important role in the diagnosis of benign and malignant mediastinal lymph nodes, with excellent results and low complication rates. The method also allows diagnosing pulmonary and mediastinal inflammatory and infectious diseases, including sarcoidosis and tuberculosis. In addition, EBUS-TBNA can be useful for diagnosing malignant mediastinal lesions such as lymphomas and mediastinal metastases of extrathoracic tumors.

The aim of this study is to evaluate the value of EBUS-TBNA in the diagnosis of lung and mediastinal lesions.

METHODS

This is a clinical and prospective observational study that included 52 patients who underwent EBUS-TBNA, over a period of 2 years (December 2016 – December 2018). All patients agreed to participate in the study and signed an informed consent form. The study was approved by the Ethics Committee on Human Research of Santa Casa de São Paulo under number 1,756,905.

Inclusion criteria

Patients who had pulmonary or mediastinal lesions, previously identified by chest CT, larger than 5 mm in size, and considered potentially accessible by EBUS-TBNA.

Exclusion criteria

Patients who had normal anatomical findings or vascular interposition that did not indicate nor allowed needle aspiration.

Procedures

EBUS-TBNA was performed on an outpatient basis under conscious or deep sedation and local anesthesia using a flexible convex ultrasound bronchoscope (Pentax® EB-1970K and Fujinon® EB-550US). Transthoracic aspirations were performed through a 22-gauge needle (Cook Medical® EchoTip® Ultra Endobronchial HD Ultrasound Needle and Medi-Globe® SonoTip® EBUS Pro Needle). All procedures were done by the same physician with previous expertise for this method. According to the IASLC - International Association for the Study of Lung Cancer® - a systematic evaluation of mediastinal stations was done, starting by placing the ultrasound probe on the left main bronchus and moving to the trachea, to study the following nodes: left pulmonary hilar (10 and 11L), left lower paratracheal (4L), subaortic (5), and upper left paratracheal (2L). The right main bronchus was studied in a similar manner, moving to the trachea to examine the following nodes: right pulmonary hilar (10 and 11 R), lower right paratracheal (4L), subaortic (5), and upper right paratracheal (2R). The subcarinal node (7) was evaluated through the main carina, on both sides. Last, an ultrasound study of the lung lesion was performed, placing the device as close as possible to it, according to the anatomical location.

All lesions found were characterized according to their location, size, echogenicity, and shape. Based on the ultrasound characteristics, potentially malignant lesions - round shape, a short axis greater than 8.3 mm, and sharp margins - were selected for ultrasound-guided fine-needle aspiration. The needle was passed into different parts of the lesion, and the negative-pressure suction technique was used with a 20 mL syringe in all cases. In this study, a rapid onsite cytologic evaluation was not performed, but a minimum of 3 punctures per lesion was set. All material was collected into a flask containing 10% formalin and sent for pathologic analysis using the cellblock technique. All pathological analyses were done by the same physician with previous expertise for this method.

Clinical follow-up

All patients were followed-up for at least 12 months after the procedure. Data on clinical progression,
complications, subsequent procedures and treatments performed were documented for analysis in this study. The following major complications were considered: excessive bleeding that was not self-limiting and that had evident clinical consequences and pneumo-thorax or mediastinitis. Adverse effects or allergic reactions to the medication used for sedation were considered anesthetic complications. Endoscopic findings such as immediate bleeding at the aspiration site, in small quantities, without hemodynamic repercussions and self-limiting, postprocedural coughing, and mild chest pain were considered inherent to the procedure and not classified as complications.

Patients with suspected lung cancer presenting negative results for malignancy by EBUS-TBNA were considered negative only after subsequent surgical confirmation (mediastinoscopy, thoracoscopy, or thora- cotomy). Patients with suspected isolated mediastinal lymphadenopathy and suspected of having a benign reactive or inflammatory disease, with negative results by EBUS-TBNA, were considered negative in the absence of clinical or radiological worsening of the lesions in a clinical follow-up of at least 12 months after the procedure. The pathologist’s interpretation of malignancy in the material obtained by EBUS-TBNA was considered sufficient and definitive for starting specific treatment.

Statistical analysis
The quantitative data were descriptively analyzed using summary measures, including the mean, median, minimum, maximum, and standard deviation (± SD). Categorical variables are expressed as frequencies and percentages. A contingency table was used to calculate the following values: sensitivity, specificity, positive predictive value, negative predictive value, and accuracy, with their respective 95% confidence intervals. The sample size (n) was calculated and estimated as 47 patients for a 95% confidence interval, considering a total error margin of 20% and an estimated proportion of 0.8571. Statistical analyses were performed using Microsoft Excel® version 16.16.1.

RESULTS
A total of 55 patients were selected for the study. Of these, 3 patients were excluded from the sample for not undergoing aspiration: 1 patient for presenting vascular interposition in the needle’s path, prohibiting safe access to the lesion; 1 patient due to normal extrinsic vascular compression findings (pulmonary artery ectasia); and 1 patient due to unsatisfactory clinical conditions (arrhythmia) for sedation, where the procedure was suspended by the anesthesia team.

The data for 52 remaining patients were thus included and analyzed in this study: mean age 61.5 ± 11.7 (26-84), 29 females and 23 males. For the procedure indication, we found: 16 (30.7%) patients with an isolated mediastinal lesion, and 36 patients (69.2%) with suspected lung cancer. Among the 52 patients, a total of 221 lesions were found and characterized as shown in Table 1. The results of the patients’ histopathological diagnoses by EBUS-TBNA are shown in Table 2.

Of the 52 subjects who underwent the procedure,
22 (42.31%) were diagnosed with locally advanced lung cancer in the mediastinum, of which 18 had a diagnosis of N2 lymph node involvement (13 pulmonary adenocarcinomas, 4 squamous cell (epidermoid) carcinomas, 1 neuroendocrine carcinoma) and 4 had a diagnosis of N3 lymph node involvement (4 pulmonary adenocarcinomas).

EBUS-TBNA confirmed the diagnosis of metastasis of other extrathoracic tumors in the mediastinum or lung in 5 patients (9.61%), including 1 patient with metastatic oropharyngeal carcinoma in the upper right paratracheal mediastinal node (level 2R); 1 patient with metastatic breast carcinoma in the left hilar mediastinal node (level 10L); 1 patient with metastatic thyroid carcinoma in the right hilar mediastinal node (level 10R); 1 patient with metastatic ovarian carcinoma in the subcarinal mediastinal node (level 7); and 1 patient with metastatic pleomorphic sarcoma in the lung parenchyma.

Furthermore, EBUS-TBNA confirmed the diagnosis of 3 patients (5.76%) with small cell carcinoma of the lung parenchyma and 1 (1.92%) patient with mediastinal sarcoidosis.

The examination diagnosed 18 patients (34.61%) as negative for malignancy, as follows: 8 patients with initial suspicion of lung cancer – all confirmed negative by subsequent surgery; 2 patients with initial suspicion of lung cancer – diagnosed as squamous cell carcinoma by subsequent surgery; and 8 patients with initial suspicion of reactive/inflammatory isolated mediastinal lymph node enlargement without evidence of other pulmonary lesions – all followed-up for a minimum of 12 months without evidence of lesion progression by imaging methods and without clinical worsening.

The aspiration was insufficient in 3 patients (5.76%), and all were referred for subsequent surgery, in which a diagnosis of lymphoma was established in 2 patients and of pulmonary adenocarcinoma in 1 patient.

The following statistical values were calculated: sensitivity 86% (74-97% CI), specificity 100%, positive predictive value 100%, negative predictive value 77% (60-95% CI) and accuracy 90% (82-98% CI). There were no major complications caused by the method used in this study.

**DISCUSSION**

In this study, data sets of 52 patients were analyzed to determine the overall efficacy of the method when applied to patients with lung and mediastinal lesions, regardless of the initial suspicion of malignant or benign disease. These results are consistent with those reported in other studies, with high values for sensitivity - 86% (CI 74-97%), specificity - 100%, positive predictive value - 100%, negative predictive value - 77% (60-95% CI), and accuracy - 90% (82-98% CI). There was also an agreement with these studies concerning the procedure’s safety, as no major complications were observed.

Likewise, the literature shows excellent results for EBUS-TBNA when used for patients with suspected lung cancer and mediastinal metastasis. In a meta-analysis that included 1066 patients, the authors demonstrated that EBUS-TBNA can be considered a potential technique for the diagnosis and staging of patients with suspected lung cancer, with a sensitivity of 90%, specificity of 99%, positive predictive value of 99%, negative predictive value of 93%, and accuracy of 96%. In another two meta-analyses, the authors confirmed the excellent diagnostic performance of the method for mediastinal staging in patients with lung cancer, with a sensitivity of 88-93% and specificity of 100%. Only 2 complications were reported (0.15%).

In Brasil and in many developing countries, there is a high prevalence of infectious and inflammatory lung diseases, in particular tuberculosis and sarcoidosis. Furthermore, many individuals are exposed to environmental and occupational pollution and various physical and chemical agents without proper personal protective care, further increasing the possibility of lung or mediastinal lesions. In our study, 8 of 52 patients (16%) were diagnosed with benign diseases, and, in one individual, histological confirmation of sarcoidosis was possible. Studies show that EBUS-TBNA is efficient and safe for the investigation of patients with suspected mediastinal sarcoidosis and tuberculosis and that it has a diagnostic yield of over 80%. Despite the high prevalence of tuberculosis in Brasil, in this study, we did not observe any patient diagnosed with this pathology by EBUS-TBNA. This may be explained by the fact that the patients were previously selected for the procedure and had no clinical, laboratory, or radiological signs of tuberculosis.

The diagnosis of lymphoproliferative disorders located in the mediastinum, including lymphoma, may be considered difficult to perform because it is necessary to collect biopsy macrofragments for adequate histopathological interpretation. In many cases, this diagnosis is only possible through surgical procedures...
and fine-needle aspiration, such as in EBUS-TBNA, is only capable of acquiring filamentary material. In this study, obtaining fragments by EBUS-TBNA for adequate histopathological interpretation was challenging, and 3 patients with material deemed insufficient were referred for surgery and diagnosed with mediastinal lymphoma. In a systematic review comprising patients with suspected mediastinal lymphoma, a large discrepancy was observed in the statistical results, with sensitivity ranging from 38-91%. Moreover, subsequent invasive surgical procedures were necessary for 13-47% of patients. Based on our findings and those in the literature, we can infer a limitation of the method for diagnosing lymphomas, and additional surgical procedures may be often required to obtain a conclusive diagnosis by collecting macrobiopsy fragments or even by removing the whole lesion.

For many years, mediastinoscopy has been considered the gold standard for the mediastinal staging of lung cancer. However, it is a more invasive procedure with higher mortality than EBUS-TBNA. Studies show a similar yield for EBUS-TBNA and mediastinoscopy for the mediastinal staging of lung cancer (sensitivity of 84% versus 86%, respectively) but with higher complication rates and lower false negative values for mediastinoscopy compared to EBUS-TBNA. Current recommendations indicate that EBUS-TBNA should be performed as the first procedure in suspected malignant mediastinal lesions, followed by mediastinoscopy in the case of negative results. In our study, 5 patients had false-negative biopsy results by EBUS-TBNA – all of whom were referred for subsequent surgery – and were confirmed as having a malignancy. Based on these results, we obtained a negative predictive value of 77% – below the other statistical results but within the range observed in other studies (67%-97%). Unlike these studies, which included only patients with suspected lung cancer, our study evaluated all individuals in a single group, including patients with suspected mediastinal lymphoma, in which EBUS-TBNA has limitations, which may explain this result.

Different studies have shown the important role of EBUS-TBNA in reducing the rate of subsequent surgical procedures necessary for diagnosing pulmonary and mediastinal lesions. In a prospective study that included 105 patients who underwent EBUS-TBNA for lung cancer staging, it was found that the method avoided the need to perform 50 subsequent invasive procedures (29 mediastinoscopies, 8 thoracotomies, 4 thoracoscopies, and 9 CT-guided chest aspirations), concluding that EBUS-TBNA can have a large impact.

**FIGURE 1. CLINICAL COURSE OF PATIENTS SUBMITTED TO EBUS-TBNA.**

EBUS-TBNA avoided subsequent surgical procedures in 19 of 52 patients (75%).
on patient management. In another study with 215 patients, the authors demonstrated that when applied to benign and malignant thoracic injuries, EBUS-TBNA was able to avoid performing 104 subsequent invasive surgical procedures and 32 hospitalizations. In another prospective and randomized study, the authors evaluated the clinical efficiency and cost-effectiveness of endoscopic ultrasound compared to standard surgical staging alone in patients with lung cancer who were potential candidates for curative surgery. The authors observed a higher rate of unnecessary thoracotomies when the staging was performed by conventional surgical methods compared to endoscopic ultrasound (18% vs. 7%, respectively). Furthermore, the study concluded that the ultrasound staging method is more tolerable and more cost-effective than surgical staging alone.

In our study, EBUS-TBNA avoided other subsequent surgical procedures in 39 of 52 patients (75%). A total of 30 patients were sent directly for specific cancer treatment, with 22 diagnosed with locally advanced disease (N2 or N3 lymph node involvement), 5 diagnosed with metastases from other extrathoracic tumors, and 3 diagnosed with small cell carcinoma. In addition, 9 patients were referred for non-oncological clinical treatment, with 1 patient diagnosed with mediastinal sarcoidosis, and 8 diagnosed with reactionary/inflammatory mediastinal lymphadenopathies (Figure 1).

**CONCLUSION**

EBUS-TBNA is a safe, effective, and valuable method. This technique can significantly reduce the rate of subsequent surgical procedures required for the diagnosis of lung and mediastinal lesions.

**Author’s Contribution**

Concept and study design: AC, RS. Data acquisition: AC, LC, FM, MC. Data analysis/interpretation: MS, FB. Statistical analysis: AC. Supervision or mentorship: LC, FM, MB, VD, RS. Manuscript writing: AC. All authors participated in the approval of the final version of the manuscript.

**Competing interests**

None for all authors.
VALUE OF ENDOBRONCHIAL ULTRASOUND-GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION (EBUS-TBNA) IN THE DIAGNOSIS OF LUNG AND MEDIASTINAL LESIONS

5. Li W, Zhang T, Chen Y, Liu C, Peng W. Diagnostic value of convex probe endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal tuberculous lymphadenitis: a systematic review and meta-analysis. Med Sci Monit. 2015;21:2064-72.
6. Senturk A, Babaoglu E, Kilic H, Hezer H, Dogan HT, Hasanoglu HC, et al. Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of lymphoma. Asian Pac J Cancer Prev. 2014;15(10):4169-73.
7. Carbonari A, Camunha M, Cinato M, Saeg M, Marioni F, Rossini L. A rare case of mediastinal metastasis of ovarian carcinoma diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). J Thorac Dis. 2015;7(10):E505-8.
8. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P, Members of IASLC Staging Committee. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(5):568-77.
9. Gill KR, Ghabril MS, Jamil LH, Hasan MK, McNeil RB, Woodward TA, et al. Endosonographic features predictive of malignancy in mediastinal lymph nodes in patients with lung cancer. Gastrointest Endosc. 2010;72(2):265-71.
10. Gahlot T, Parakh U, Verma K, Bhalotra B, Jain N. Endobronchial ultrasound-guided transbronchial needle aspiration in diagnosing mediastinal lymphadenopathy. Lung India. 2017;34(3):241-6.
11. Dong X, Qiu X, Liu Q, Ji J. Endobronchial ultrasound-guided transbronchial needle aspiration in the mediastinal staging of non-small cell lung cancer: a meta-analysis. Ann Thorac Surg. 2013;96(4):1502-7.
12. Gu P, Zhao YZ, Jiang LY, Zhang W, Xin Y, Han BH. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer. 2009;45(8):1389-96.
13. Adams K, Shah PL, Edmonds L, Lim E. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax. 2009;64(9):751-62.
14. Kheir F, Itani A, Assasa O, Alrajeh AH. The utility of endobronchial ultrasound-guided transbronchial needle aspiration in lymphoma. Endosc Ultrasound. 2016;5(1):43-8.
15. Ge X, Guan W, Han F, Guo X, Jin Z. Comparison of endobronchial ultrasound-guided fine needle aspiration and video-assisted mediastinoscopy for mediastinal staging of lung cancer. Lung. 2015;193(3):757-66.
16. Sehgal IS, Dhonukshe S, Aggarwal AN, Behera D, Agarwal R. Endosonography versus mediastinoscopy in mediastinal staging of lung cancer: systematic review and meta-analysis. Ann Thorac Surg. 2016;102(3):1747-55.
17. Yasufuku K, Chiyotani M, Koh E, Moriya Y, Iyoda A, Sekine Y, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer. Lung Cancer. 2005;50(3):347-54.
18. Steinfort DP, Hew MJ, Irving LB. Bronchoscopic evaluation of the mediastinum using endobronchial ultrasound: a description of the first 216 cases carried out at an Australian tertiary hospital. Intern Med J. 2011;41(12):815-24.
19. Sharples LD, Jackson C, Wheaton E, Griffith G, Annema JT, Dooms C, et al. Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic ultrasound relative to surgical staging in potentially resectable lung cancer: results from the ASTER randomized controlled trial. Health Technol Assess. 2012;16(18):1-75, iii-iv.

Regarding the article "VALUE OF ENDOBRONCHIAL ULTRASOUND-GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION (EBUS-TBNA) IN THE DIAGNOSIS OF LUNG AND MEDIASTINAL LESIONS" with DOI number: https://dx.doi.org/10.1590/1806-9282.66.9.1210, published in Journal of the Brazilian Medical Association, 2020;66(9), page 1210, changed:

From: Hospital Santa Casa de São Paulo – Departamento de Cirurgia Toráxica, São Paulo, SP, Brasil
To: Hospital Santa Casa de São Paulo – Departamento de Cirurgia Torácica, São Paulo, SP, Brasil.

From: Inclusion criteria
Patients who had normal anatomical findings or vascular interposition that did not indicate nor allowed needle aspiration.
To: Patients who had normal anatomical findings or vascular interposition that did not indicate nor allowed needle aspiration.

From: The following major complications were considered: excessive bleeding that was not self-limiting and that had evident clinical consequences and lung, pneumo-thorax, or pneumomediastinum infections.
To: The following major complications were considered: excessive bleeding that was not self-limiting and that had evident clinical consequences and pneumo-thorax or mediastinitis.